Azitra Logo
Azitra, Inc., a clinical-stage biopharmaceutical company based in Branford, Connecticut, will present recent developments at the upcoming H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025, in New York City. Co-founder and Chief Operating Officer Travis Whitfill, PhD, MPH, is set to deliver a virtual presentation on September 8 at 07:00 AM ET, where he will discuss significant updates regarding the company’s clinical pipeline.
During the pre-recorded presentation, Dr. Whitfill will focus on the promising safety results of the Phase 1b clinical trial for Azitra’s lead program, ATR-12, which targets Netherton syndrome. This rare skin condition currently lacks approved treatment options and can be severe, presenting challenges for those affected. The company has also announced that the first patient has been dosed in the Phase 1/2 clinical trial of the ATR-04 program, aimed at addressing EGFR inhibitor-associated dermal toxicity in adults. The trial’s design was previously showcased at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Key Developments in Clinical Trials
Azitra’s programs leverage a proprietary platform that includes a microbial library of approximately 1,500 bacterial strains, enhanced by artificial intelligence and machine learning technology. This innovative approach enables the company to develop therapies tailored to the specific needs of dermatological conditions.
The ATR-12 program involves a Phase 1b clinical trial specifically for adult patients suffering from Netherton syndrome. Meanwhile, the ATR-04 program is focused on patients experiencing rash due to EGFR inhibitors, a condition affecting around 150,000 people in the U.S. Notably, Azitra has received Fast Track designation from the FDA for this treatment, emphasizing its potential significance in the market.
During the conference, Dr. Whitfill will also engage in one-on-one meetings with registered investors and potential partners to further elaborate on Azitra’s business strategy, recent achievements, and future milestones.
About Azitra, Inc.
Founded with the mission to develop innovative therapies for precision dermatology, Azitra, Inc. has made significant strides in addressing unmet medical needs through its clinical programs. The company is dedicated to advancing treatments for complex skin diseases, such as Netherton syndrome, which can lead to life-threatening complications in infancy and lifelong challenges for survivors.
Azitra’s commitment to research and development is reflected in its active investigational new drug (IND) application for the ATR-04 program, which is advancing in clinical testing. As the company prepares for its presentation at the H.C. Wainwright conference, stakeholders will be looking for insights into how these innovations can shape the future of dermatological care.
For more information about Azitra and its initiatives, visit https://azitrainc.com.
This announcement includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements may include expectations regarding clinical trials and regulatory approvals, which are subject to various risks and uncertainties that could cause actual results to differ materially. Azitra disclaims any obligation to update these statements unless legally required.
